Pharmaceutical-regulation risk relating to cosmetics and quasi-drugs
First written in FY2016. 1 of 3 entries say "Reframed", first in FY2017. Latest entry: FY2024.
3 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「The manufacture, import and sale of cosmetics handled by the Group are subject to regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, which is intended to ensure the quality, efficacy and safety of pharmaceuticals, medical devices and other products, and full ingredient labeling and other requirements are mandatory.」
The risks associated with regulations governing the manufacture and marketing of cosmetics and quasi-drugs, including the expiry or revocation of licenses, are being reconfirmed. - FY2017ReframedAnnual report
「The manufacture, import and sale of the cosmetics handled by the Company are subject to regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, which is intended to ensure the quality, efficacy and safety of pharmaceuticals, quasi-drugs, cosmetics and other products.」
The description of the legislation and related regulations has been updated from the former reference to the Pharmaceutical Affairs Act to the current Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. - FY2016First statedAnnual report
「The Company has obtained licenses for cosmetic manufacturing, cosmetic manufacturing (packaging, labeling and storage), cosmetic manufacturing and marketing, quasi-drug manufacturing, and quasi-drug manufacturing and marketing, and manufactures, imports and sells cosmetics. In accordance with the relevant law, it works to maintain quality control and other standards.」
The disclosure states that the expiry or revocation of licenses could affect the Company's performance.